Aprea Therapeutics, Inc. — Director's Dealing 2021

Mar 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aprea Therapeutics, Inc. (APRE)
CIK: 0001781983
Period of Report: 2021-02-25

Reporting Person: Coiante Scott M (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-25	Common Stock	A	33000	—	Acquired	35500	Direct
2021-02-25	Common Stock	A	63500	—	Acquired	99000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-25	Stock Option (right to Buy)	$6	A	143000	Acquired	2031-02-25	Common Stock (143000)	Direct

Footnotes

F1: These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 11,000 shares on February 25, 2022, (ii) 11,000 shares on February 25, 2023 and (iii) 11,000 shares on February 25, 2024, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

F2: These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 21,166 shares on August 25, 2021, (ii) 21,167 shares on February 25, 2022 and (iii) 21,167 shares on August 25, 2022, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

F3: Twenty-five percent of these options vest on February 25, 2022, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions.